Results 201 to 210 of about 136,779 (265)

Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports. [PDF]

Cancer Manag Res
Chen Q, Lin X, Chen L, Yao J, Yan Y, Zhang X, Yang D, Lin X, Chen S, Chen X, Yu N.   +10 more
europepmc   +1 more source

Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy

Advanced Science, EarlyView.
We developed an ultrasound‐controlled biomimetic nanoplatform, mRNA/V@M NPs, to co‐deliver CD74 mRNA and V‐9302 for fibrotic TNBC therapy. CD74 mRNA reprograms myCAFs into antigen‐presenting apCAF cells through the CD74‐MHC II pathway, while V‐9302 induces ICD and activates MHC I‐CD8+ T cell immunity.
Chen Ai, Weikai Sun, Yuxuan Zhao, Daqian Sun, Ting Meng, Yafei Qi, Fengyang Jiang, Jintang Sun, Zhiliang Gao, Dexin Yu   +9 more
wiley   +1 more source

Bright side of the dark genome: antigens for next-gen cancer vaccines. [PDF]

J Immunother Cancer
Wang XS, Fox BA.
europepmc   +1 more source

Identifying a Csmd3+ Microglial Subpopulation that Drives Cold‐to‐Hot Transition and Immune‐Cure in Glioblastoma

Advanced Science, EarlyView.
The study establishes an immune‐cure (ICu) mouse model based on a TMEMed G422TN‐GBM system that faithfully recapitulates human TMEMed GBM. scRNA‐seq analysis reveals a Csmd3+ microglial subset with innate immune memory (IIM) potential that potently suppresses GBM growth, drives a TME cold‐to‐hot transition, and induces 100% ICu in long‐term survival ...
Hai‐Feng Jiang, Pan‐Pan Gao, Yu‐Wen Du, Li‐Qin Wu, En‐Zhi Yin, Qi An, Ze‐Hua Ding, Jin‐Wen Shi, Ya Shu, Ruoqiao Chen, Feng Liu, Mingfeng Li, Xiao Qian Chen   +12 more
wiley   +1 more source

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection. [PDF]

Front Immunol
Xu H, Li B, Yang J, Tang X.
europepmc   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives. [PDF]

Biochem Med (Zagreb)
de Almeida GB, Dos Santos MM, de Oliveira Barbosa D, Conceição RR, de Almeida Lopes B, de Melo Santos HH, Marchioro SB.   +6 more
europepmc   +1 more source

[Malignant urologic neoplasms and HLA antigen (1)].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1983
I, Kondo, H, Fujii, K, Suzuki, A, Kohdaira, K, Saito   +4 more
openaire   +1 more source

Therapy-induced immunoediting and the evolution of cancer immune escape. [PDF]

Front Immunol
Meng S, Wang Z.
europepmc   +1 more source

Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts. [PDF]

Blood Cancer J
Teras LR, Landry M, Hodge JM, Pal Choudhury P, Birmann BM, Cozen W, Hofmann JN, Jeske R, Purdue MP, Cerhan JR, Le Marchand L, Babi A, Patel AV, Waterboer T.   +13 more
europepmc   +1 more source